New study to track cystic fibrosis drugs in pregnancy and breast milk
NCT ID NCT04940533
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how cystic fibrosis medications (CFTR modulators) change in the body during pregnancy and after childbirth in 30 women. Researchers will measure drug levels in blood, breast milk, and umbilical cord blood. The goal is to understand how these drugs work in pregnant and breastfeeding mothers to help guide safe use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult females receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulation therapy who are pregnant or breastfeeding.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female 18 years of age and older * Female who has a diagnosis of cystic fibrosis * Female who is taking cystic fibrosis transmembrane conductance regulator (CFTR) modulator medication during pregnancy and postpartum Exclusion Criteria: * Female \< 18 years of age * Female with cystic fibrosis who is not taking cystic fibrosis transmembrane conductance regulator (CFTR) modulator medication during pregnancy and postpartum * Participant has contraindication to breastfeeding or not planning to breastfeed
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- How much lidocaine reaches a newborn during an urgent C-Section?
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Could pregnant patients skip clinic visits and monitor their baby from home?
- Can a video session get pregnant women to seek more health care?